REG - EKF Diagnostics Hldg - Notice of Results and Investor Presentation

EKF Diagnostics HoldingsAnnouncement

01/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230301:nRSA3991Ra&default-theme=true

RNS Number : 3991R  EKF Diagnostics Holdings PLC  01 March 2023

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

Notice of Preliminary Results and Investor Presentation

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care
business, will announce its preliminary results for the year ended 31 December
2022, on Tuesday 28 March 2023.

 

Investor Presentation

 

Julian Baines, Executive Chair, and Marc Davies, Chief Financial Officer, will
be hosting a live online presentation relating to the preliminary results via
the Investor Meet Company platform at 4.30 pm on Tuesday 28 March 2023. The
presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and register for the
presentation here:
https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor
(https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor)

 

Investors who already follow EKF on the Investor Meet Company platform will
automatically be invited.

 

A recording of the presentation, a PDF of the slides used, and responses to
the Q&A session will be available on the Investor Meet Company platform
afterwards.

 

 

 EKF Diagnostics Holdings plc                                 www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair / Marc Davies, CFO             Tel: +44 (0)29 2071 0570

 Singer Capital Markets (Nominated Adviser & Joint Broker)                                  Tel: +44 (0)20 7496 3000
 Aubrey Powell / George Tzimas / Oliver Platts

 Walbrook PR Limited               Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Lianne Applegarth  Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is a leading global diagnostics business with custom manufacturing
facilities across sites in the US, UK and Europe for a variety of life science
products. EKF is focussed on the following areas:

 

 Point-of-Care           Providing a portfolio of Point-of-Care analysers and consumables, particularly
                         for use in the area of Hematology and Diabetes, for use in hospital and
                         research laboratories, doctor's offices, blood banks and for in-field anaemia
                         screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit,
                         HbA1c, glucose and lactate analysers in regular use across more than 100
                         countries.

 Central Laboratory      Clinical chemistry, Small lab analysers, Centrifuges

                         Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycated Albumin, Glycated Serum
                         Protein, Nitro-tab, Procalcitonin

 Life Sciences           Enzyme fermentation, Custom products and Bulk fermentation

 Contract Manufacturing  Bulk formulation, Sample collection kits, Private labelling, Molecular and
                         forensic kits

 Laboratory Testing      Laboratory testing services certified under the Clinical Laboratory
                         Improvement Amendments ("CLIA") for high complexity testing.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORSELFWAEDSEFE